Genetic pathways to glioblastomas
Генетические пути развития глиобластом
2005-02-28
SCID: 54.1/tynctg9s
Discuss with AI
LOH 10qMGMT promoter methylationTP53 mutationsprimary glioblastomasecondary glioblastoma
Figures from the paper
Abstract (AI)
Glioblastomas, the most frequent and malignant human brain tumors, may develop de novo (primary glioblastoma) or by progression from low-grade or anaplastic astrocytoma (secondary glioblastoma). These glioblastoma subtypes constitute distinct disease entities that affect patients of different ages and develop through different genetic pathways. Our recent population-based study in the Canton of Zürich, Switzerland, shows that primary glioblastomas develop in older patients (mean age, 62 years) and typically show LOH on chromosome 10q (69%) and other genetic alterations (EGFR amplification, TP53 mutations, p16INK4a deletion, and PTEN mutations) at frequencies of 24-34%. Secondary glioblastomas develop in younger patients (mean, 45 years) and frequently show TP53 mutations (65%) and LOH 10q (63%). Common to both primary and secondary glioblastoma is LOH on 10q, distal to the PTEN locus; a putative suppressor gene at 10q25-qter may be responsible for the glioblastoma phenotype. Of the TP53 point mutations in secondary glioblastomas, 57% were located in hotspot codons 248 and 273, while in primary glioblastomas, mutations were more widely distributed. Furthermore, G:C-->A:T mutations at CpG sites were more frequent in secondary than in primary glioblastomas (56% vs 30%). These data suggest that the TP53 mutations in these glioblastoma subtypes arise through different mechanisms. There is evidence that G:C-->A:T transition mutations at CpG sites in the TP53 gene are significantly more frequent in low-grade astrocytomas with promoter methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene than in those without methylation. This suggests that, in addition to deamination of 5-methylcytosine (the best known mechanism of formation of G:C-->A:T transitions at CpG sites), involvement of alkylating agents that produce O6-methylguanine or related adducts recognized by MGMT cannot be excluded in the pathway leading to secondary glioblastomas.
Key Findings
1
Both glioblastoma subtypes share 10q loss distal to PTEN, implicating a putative tumor-suppressor gene at 10q25-qter in glioblastoma development.
2
Primary and secondary glioblastomas are distinct disease entities affecting different age groups and developing through different genetic pathways.
3
Primary glioblastomas occur in older patients (mean 62 years) and commonly exhibit 10q loss of heterozygosity, EGFR amplification, TP53 mutations, p16INK4a deletion, and PTEN mutations.
4
Secondary glioblastomas occur in younger patients (mean 45 years) and frequently harbor TP53 mutations (65%) and 10q loss of heterozygosity (63%).
5
TP53 mutations differ between subtypes: secondary tumors concentrate mutations in hotspot codons 248 and 273, whereas primary tumors show broader mutation distributions; CpG-site G:C→A:T mutations are more frequent in secondary tumors (56% versus 30%).
6
The mutation patterns suggest distinct mechanisms of TP53 alteration, potentially involving MGMT-related processing of alkylation-induced O6-methylguanine in the pathway to secondary glioblastoma.
Research Object
Primary and secondary glioblastomas
Research Subject
Distinct genetic pathways and molecular alterations underlying glioblastoma development, including TP53 mutation patterns, chromosome 10q loss of heterozygosity, and MGMT-associated mechanisms
Publication Details
Publication Date
2005-02-28
Journal
Publisher
ISSN
Cited by
272
Access Type
Author Information
Download PDF
Subscribe to digest